Court Rules In Pfizer's Favor In Norvasc Patent Case

Law360, New York (January 31, 2007, 12:00 AM EST) -- In yet another setback for Dutch drug maker Synthon Pharmaceuticals Inc., a U.S. judge has agreed with defendant Pfizer Inc. that Synthon’s patent for generic Norvasc was gleaned through inequitable conduct.

According to a sealed order issued Jan. 29, Synthon intentionally withheld from the U.S. Patent and Trademark Office certain publications by Pfizer and other information that described the process Synthon was patenting.

Due to Synthon’s alleged behavior during patent prosecution, the patent-in-suit was deemed unenforceable and not infringed by Judge T. S. Ellis III in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.